{"url_path":"/sec/ikt/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-344623-index.html","accession_number":"0001193125-26-344623","cik":"0001750149","ticker":"IKT","issuer_name":"Inhibikase Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-344623-index.html","primary_entity_key":"0001750149","primary_entity_name":"Inhibikase Therapeutics, Inc."},"word_count":139,"has_tables":true,"body_markdown":"Item 2.02.\n\nResults of Operations and Financial Condition.\n\nOn August 11, 2026, Inhibikase Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}